Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma

Ryumon,Shoji; Okui,Tatsuo; Kunisada,Yuki; Kishimoto,Koji; Shimo,Tsuyoshi; Hasegawa,Kazuaki; Ibaragi,Soichiro; Akiyama,Kentaro; Thu Ha,Nguyen  Thi; Monsur Hassan,Nur  Mohammad; Sasaki,Akira

doi:10.3892/or.2019.7367

Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma

Authors:
- Shoji Ryumon
- Tatsuo Okui
- Yuki Kunisada
- Koji Kishimoto
- Tsuyoshi Shimo
- Kazuaki Hasegawa
- Soichiro Ibaragi
- Kentaro Akiyama
- Nguyen Thi Thu Ha
- Nur Mohammad Monsur Hassan
- Akira Sasaki
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700‑8525, Japan, Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Hokkaido 061‑0293, Japan, Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700‑8525, Japan, School of Dentistry and Health Sciences, Charles Sturt University, Orange, NSW 2800, Australia
Published online on: October 10, 2019 https://doi.org/10.3892/or.2019.7367
Pages: 2611-2621
Copyright: © Ryumon et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platinum‑based antitumor agents have been widely used to treat head and neck squamous cell carcinoma (HNSCC) and numerous other malignancies. Cisplatin is the most frequently used platinum‑based antitumor agent, however drug resistance and numerous undesirable side effects limit its clinical efficacy for cancer patients. Cancer cells discharge cisplatin into the extracellular space via copper transporters such as ATPase copper transporting beta (ATP7B) in order to escape from cisplatin‑induced cell death. In the present study, it was demonstrated for the first time that the copper chelator ammonium tetrathiomolybdate (TM) has several promising effects on cisplatin and HNSCC. First, TM suppressed the ATP7B expression in HNSCC cell lines in vitro, thereby enhancing the accumulation and apoptotic effect of cisplatin in the cancer cells. Next, it was revealed that TM enhanced the antitumor effect of cisplatin in HNSCC cell tumor progression in a mouse model of bone invasion, which is important since HNSCC cells frequently invade to facial bone. Finally, it was demonstrated that TM was able to overcome the cisplatin resistance of a human cancer cell line, A431, via ATP7B depression in vitro.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et al: Global, Regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A Systematic analysis for the global burden of disease study. JAMA Oncol. 4:1553–1568. 2018. View Article : Google Scholar : PubMed/NCBI
2	Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar : PubMed/NCBI
3	Carvalho AL, Nishimoto IN, Califano JA and Kowalski LP: Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer. 114:806–816. 2005. View Article : Google Scholar : PubMed/NCBI
4	Guan J, Li Q, Zhang Y, Xiao N, Chen M, Zhang Y, Li L and Chen L: A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget. 7:7110–7119. 2016. View Article : Google Scholar : PubMed/NCBI
5	Nagasaka M, Zaki M, Issa M, Kim H, Abrams J and Sukari A: Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 127:2260–2264. 2017. View Article : Google Scholar : PubMed/NCBI
6	Gao Y and Liu D: The roles of excision repair cross-complementation group 1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: A systematic review and meta-analysis. Oral Oncol. 51:570–577. 2015. View Article : Google Scholar : PubMed/NCBI
7	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
8	Mehmood RK: Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncol Rev. 8:2562014. View Article : Google Scholar : PubMed/NCBI
9	Chvalova K, Brabec V and Kasparkova J: Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res. 35:1812–1821. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, et al: A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 25:2230–2236. 2014. View Article : Google Scholar : PubMed/NCBI
11	Damia G and Broggini M: Platinum resistance in ovarian cancer: Role of DNA repair. Cancers (Basel). 11:E1192019. View Article : Google Scholar : PubMed/NCBI
12	Fadejeva I, Olschewski H and Hrzenjak A: MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
13	Lambert IH and Sorensen BH: Facilitating the cellular accumulation of Pt-based chemotherapeutic drugs. Int J Mol Sci. 19(pii): E22492018. View Article : Google Scholar : PubMed/NCBI
14	Leonhardt K, Gebhardt R, Mossner J, Lutsenko S and Huster D: Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. J Biol Chem. 284:7793–7802. 2009. View Article : Google Scholar : PubMed/NCBI
15	Inesi G: Molecular features of copper binding proteins involved in copper homeostasis. IUBMB Life. 69:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
16	Roberts EA: Update on the diagnosis and management of wilson disease. Curr Gastroenterol Rep. 20:562018. View Article : Google Scholar : PubMed/NCBI
17	Morisawa A, Okui T, Shimo T, Ibaragi S, Okusha Y, Ono M, Nguyen TTH, Hassan NMM and Sasaki A: Ammonium tetrathiomolybdate enhances the antitumor effects of cetuximab via the suppression of osteoclastogenesis in head and neck squamous carcinoma. Int J Oncol. 52:989–999. 2018.PubMed/NCBI
18	Mese H, Sasaki A, Alcalde RE, Nakayama S and Matsumura T: Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell. Chemotherapy. 44:414–420. 1998. View Article : Google Scholar : PubMed/NCBI
19	Mese H, Sasaki A, Nakayama S, Alcalde RE and Matsumura T: The role of caspase family protease, caspase-3 on cisplatin-induced apoptosis in cisplatin-resistant A431 cell line. Cancer Chemother Pharmacol. 46:241–245. 2000. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Chan N, Willis A, Kornhauser N, Ward MM, Lee SB, Nackos E, Seo BR, Chuang E, Cigler T, Moore A, et al: Influencing the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clin Cancer Res. 23:666–676. 2017. View Article : Google Scholar : PubMed/NCBI
22	Chisholm CL, Wang H, Wong AH, Vazquez-Ortiz G, Chen W, Xu X and Deng CX: Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin. Oncotarget. 7:84439–84452. 2016. View Article : Google Scholar : PubMed/NCBI
23	Park SJ, Kim MJ, Kim YK, Kim SM, Park JY and Myoung H: Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Cancer Lett. 292:54–63. 2010. View Article : Google Scholar : PubMed/NCBI
24	Ishida S, Lee J, Thiele DJ and Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA. 99:14298–14302. 2002. View Article : Google Scholar : PubMed/NCBI
25	Xu X, Duan L, Zhou B, Ma R, Zhou H and Liu Z: Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol. 39:786–792. 2012. View Article : Google Scholar : PubMed/NCBI
26	Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II and Siddik ZH: Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 85:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
27	Molloy SA and Kaplan JH: Copper-dependent recycling of hCTR1, the human high affinity copper transporter. J Biol Chem. 284:29704–29713. 2009. View Article : Google Scholar : PubMed/NCBI
28	Fang T, Chen W, Sheng Y, Yuan S, Tang Q, Li G, Huang G, Su J, Zhang X, Zang J and Liu Y: Tetrathiomolybdate induces dimerization of the metal-binding domain of ATPase and inhibits platination of the protein. Nat Commun. 10:1862019. View Article : Google Scholar : PubMed/NCBI
29	Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK and Moore RG: Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers. Sci Rep. 5:159112015. View Article : Google Scholar : PubMed/NCBI
30	Okui T, Shimo T, Fukazawa T, Kurio N, Hassan NM, Honami T, Takaoka M, Naomoto Y and Sasaki A: Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Mol Cancer Ther. 9:2960–2969. 2010. View Article : Google Scholar : PubMed/NCBI
31	Kilari D, Guancial E and Kim ES: Role of copper transporters in platinum resistance. World J Clin Oncol. 7:106–113. 2016. View Article : Google Scholar : PubMed/NCBI
32	Fu S, Naing A, Fu C, Kuo MT and Kurzrock R: Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther. 11:1221–1225. 2012. View Article : Google Scholar : PubMed/NCBI